This company has been marked as potentially delisted and may not be actively trading. Anchiano Therapeutics (ANCN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock ANCN vs. TPST, AKTX, RVPH, KPTI, IRD, FGEN, CNTB, MRNS, ATHE, and LEXXShould you be buying Anchiano Therapeutics stock or one of its competitors? The main competitors of Anchiano Therapeutics include Tempest Therapeutics (TPST), Akari Therapeutics (AKTX), Reviva Pharmaceuticals (RVPH), Karyopharm Therapeutics (KPTI), Opus Genetics (IRD), FibroGen (FGEN), Connect Biopharma (CNTB), Marinus Pharmaceuticals (MRNS), Alterity Therapeutics (ATHE), and Lexaria Bioscience (LEXX). These companies are all part of the "medical" sector. Anchiano Therapeutics vs. Tempest Therapeutics Akari Therapeutics Reviva Pharmaceuticals Karyopharm Therapeutics Opus Genetics FibroGen Connect Biopharma Marinus Pharmaceuticals Alterity Therapeutics Lexaria Bioscience Anchiano Therapeutics (NASDAQ:ANCN) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, community ranking, dividends, analyst recommendations, institutional ownership and valuation. Do institutionals & insiders have more ownership in ANCN or TPST? 9.1% of Anchiano Therapeutics shares are owned by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are owned by institutional investors. 6.9% of Anchiano Therapeutics shares are owned by company insiders. Comparatively, 4.7% of Tempest Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts recommend ANCN or TPST? Tempest Therapeutics has a consensus price target of $9.33, suggesting a potential upside of 1,205.36%. Given Tempest Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tempest Therapeutics is more favorable than Anchiano Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anchiano Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Tempest Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation & earnings, ANCN or TPST? Tempest Therapeutics is trading at a lower price-to-earnings ratio than Anchiano Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnchiano TherapeuticsN/AN/A-$27.12M-$3.46-0.33Tempest TherapeuticsN/AN/A-$29.49M-$1.50-0.48 Is ANCN or TPST more profitable? Anchiano Therapeutics' return on equity of 36.08% beat Tempest Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Anchiano TherapeuticsN/A 36.08% 27.40% Tempest Therapeutics N/A -187.44%-82.61% Does the MarketBeat Community favor ANCN or TPST? Tempest Therapeutics received 44 more outperform votes than Anchiano Therapeutics when rated by MarketBeat users. Likewise, 66.23% of users gave Tempest Therapeutics an outperform vote while only 65.91% of users gave Anchiano Therapeutics an outperform vote. CompanyUnderperformOutperformAnchiano TherapeuticsOutperform Votes5865.91% Underperform Votes3034.09% Tempest TherapeuticsOutperform Votes10266.23% Underperform Votes5233.77% Which has more volatility & risk, ANCN or TPST? Anchiano Therapeutics has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Comparatively, Tempest Therapeutics has a beta of -2.33, meaning that its share price is 333% less volatile than the S&P 500. Does the media prefer ANCN or TPST? In the previous week, Tempest Therapeutics had 18 more articles in the media than Anchiano Therapeutics. MarketBeat recorded 18 mentions for Tempest Therapeutics and 0 mentions for Anchiano Therapeutics. Tempest Therapeutics' average media sentiment score of 0.13 beat Anchiano Therapeutics' score of 0.00 indicating that Tempest Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Anchiano Therapeutics Neutral Tempest Therapeutics Neutral SummaryTempest Therapeutics beats Anchiano Therapeutics on 9 of the 15 factors compared between the two stocks. Remove Ads Get Anchiano Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ANCN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANCN vs. The Competition Export to ExcelMetricAnchiano TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.39M$6.73B$5.55B$7.50BDividend YieldN/A2.79%5.35%4.04%P/E Ratio7.537.0222.9418.10Price / SalesN/A199.21361.5886.56Price / CashN/A65.6738.1634.64Price / Book0.565.926.494.00Net Income-$27.12M$142.59M$3.21B$247.18M Anchiano Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANCNAnchiano TherapeuticsN/A$1.13+8.7%N/A+34.9%$8.39MN/A7.5316TPSTTempest Therapeutics2.9872 of 5 stars$0.74-4.4%$9.33+1,164.7%-85.1%$32.21MN/A-0.4820Earnings ReportShort Interest ↓Analyst RevisionGap DownAKTXAkari TherapeuticsN/A$1.21-5.0%N/A-27.2%$32.07MN/A0.009Upcoming EarningsAnalyst ForecastGap UpRVPHReviva Pharmaceuticals3.9731 of 5 stars$0.95-5.6%$11.40+1,095.2%-83.8%$31.90MN/A-0.865Earnings ReportAnalyst ForecastNews CoverageKPTIKaryopharm Therapeutics3.3871 of 5 stars$3.74-10.1%$57.50+1,437.4%-80.6%$31.48M$145.24M-3.67380Gap DownHigh Trading VolumeIRDOpus Genetics1.9866 of 5 stars$0.98-2.8%$8.00+714.8%N/A$31.46M$8.38M-0.9014Earnings ReportUpcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageFGENFibroGen4.396 of 5 stars$0.31-1.2%$10.00+3,126.8%-85.8%$31.27M$29.62M-0.25570Analyst ForecastAnalyst RevisionNews CoverageGap DownCNTBConnect Biopharma3.3176 of 5 stars$0.55-19.1%$8.00+1,354.5%-69.7%$30.39M$24.12M0.00110Analyst ForecastAnalyst RevisionGap UpHigh Trading VolumeMRNSMarinus Pharmaceuticals2.3165 of 5 stars$0.55-0.2%$4.79+771.6%-93.8%$30.32M$30.99M-0.22110Analyst ForecastATHEAlterity Therapeutics2.1704 of 5 stars$3.39-1.4%$12.00+253.9%+69.4%$30.07MN/A0.0010LEXXLexaria Bioscience2.4532 of 5 stars$1.71-0.6%$7.00+309.4%-51.9%$30.02M$496,923.00-3.427Upcoming EarningsNews CoverageGap Up Remove Ads Related Companies and Tools Related Companies TPST Alternatives AKTX Alternatives RVPH Alternatives KPTI Alternatives IRD Alternatives FGEN Alternatives CNTB Alternatives MRNS Alternatives ATHE Alternatives LEXX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANCN) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anchiano Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anchiano Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
